Trends in Outcomes and Hospitalization Charges among Mechanically Ventilated Patients with Myasthenia Gravis in the United States
- PMID: 23675139
- PMCID: PMC3614787
Trends in Outcomes and Hospitalization Charges among Mechanically Ventilated Patients with Myasthenia Gravis in the United States
Abstract
Introduction: To assess the impact of new therapeutic strategies on outcome and cost of hospitalization among patients with myasthenia gravis (MG) who are mechanically ventilated in United States.
Methods: Using a retrospective analysis of cross sectional survey, we determined the rates of occurrence, in-hospital outcomes, and mean hospital charges for patients hospitalized with MG requiring mechanical ventilation in 1991-1992 using the Nationwide Inpatient Survey (NIS) and compared these outcomes with homologous data from 2001-2002. NIS is the largest all-payer inpatient care database in the United States.
Results: When comparing data from 2001-2002 with data from 1991-1992, we found a higher number of admissions for MG that required mechanical ventilation (994 vs. 652). The proportion of women was similar (53% vs. 60%). The average age (in years ± standard deviation) was significantly higher (65 ± 17 vs. 58 ± 18, p=0.0002). The length of hospitalization (in days ± standard deviation) was not different (22 ± 19 vs. 21 ± 16). Discharge to home occurred less frequently (29% vs. 60%, p=0.0001) and in hospital mortality minimally lower (13% vs. 15%). There was a significant increase in mean hospital charges ($118,000 vs. $84,100 adjusted for inflation, p=0.0001). In hospital mortality was higher among urban teaching hospitals compared with urban non teaching hospitals in 2001-2002.
Conclusions: Despite improvement in therapeutic strategies from 1991 to 2002, there was only a modest reduction in mortality and no substantial reduction of length of hospitalization for patients with MG requiring mechanical ventilation.
Keywords: cost; length of stay; mechanical ventilation; mortality; myasthenia crisis; myasthenia gravis; outcome.
Similar articles
-
Discharge dispositions, complications, and costs of hospitalization in spinal cord tumor surgery: analysis of data from the United States Nationwide Inpatient Sample, 2003-2010.J Neurosurg Spine. 2014 Feb;20(2):125-41. doi: 10.3171/2013.9.SPINE13274. Epub 2013 Nov 29. J Neurosurg Spine. 2014. PMID: 24286530
-
Trends in Outcomes and Hospitalization Charges of Infant Botulism in the United States: A Comparative Analysis Between Kids' Inpatient Database and National Inpatient Sample.Pediatr Neurol. 2017 Feb;67:53-58. doi: 10.1016/j.pediatrneurol.2016.10.009. Epub 2016 Oct 20. Pediatr Neurol. 2017. PMID: 28041655
-
Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001.Stroke. 2007 Jul;38(7):2180-4. doi: 10.1161/STROKEAHA.106.467506. Epub 2007 May 24. Stroke. 2007. PMID: 17525400
-
Improved outcomes for patients with cerebrovascular malformations at high-volume centers: the impact of surgeon and hospital volume in the United States, 2000-2009.J Neurosurg. 2017 Jul;127(1):69-80. doi: 10.3171/2016.7.JNS15925. Epub 2016 Oct 14. J Neurosurg. 2017. PMID: 27739942
-
Hospitalizations and Mortality From Myasthenia Gravis: Trends From 2 US National Datasets.Neurology. 2024 Jan 23;102(2):e207863. doi: 10.1212/WNL.0000000000207863. Epub 2023 Dec 18. Neurology. 2024. PMID: 38165317
Cited by
-
Assessing the length of hospital stay for patients with myasthenia gravis based on the data mining MARS approach.Front Neurol. 2023 Dec 14;14:1283214. doi: 10.3389/fneur.2023.1283214. eCollection 2023. Front Neurol. 2023. PMID: 38156090 Free PMC article.
-
Patients With Myasthenia Gravis With Acute Onset of Dyspnea: Predictors of Progression to Myasthenic Crisis and Prognosis.Front Neurol. 2021 Nov 18;12:767961. doi: 10.3389/fneur.2021.767961. eCollection 2021. Front Neurol. 2021. PMID: 34867753 Free PMC article.
-
US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization.Drugs Real World Outcomes. 2024 Dec;11(4):593-601. doi: 10.1007/s40801-024-00457-8. Epub 2024 Oct 29. Drugs Real World Outcomes. 2024. PMID: 39470958 Free PMC article.
-
Health care costs and resource utilization among patients with myasthenia gravis in the United States.J Manag Care Spec Pharm. 2025 May;31(5):472-481. doi: 10.18553/jmcp.2025.31.5.472. J Manag Care Spec Pharm. 2025. PMID: 40298306 Free PMC article.
-
Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States.Front Neurol. 2022 Jan 18;12:809999. doi: 10.3389/fneur.2021.809999. eCollection 2021. Front Neurol. 2022. PMID: 35115997 Free PMC article.
References
-
- Drachman DB. Myasthenia gravis. N. Engl. J. Med. 1994;330:1797–1810. - PubMed
-
- Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol. 1984;16:519–534. - PubMed
-
- Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48:1253–1260. - PubMed
-
- Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann. N. Y. Acad. Sci. 1981;377:670–677. - PubMed
-
- Gracey DR, Divertie MB, Howard FM., Jr Mechanical ventilation for respiratory failure in myasthenia gravis. Two-year experience with 22 patients. Mayo Clin. Proc. 1983;58:597–602. - PubMed
LinkOut - more resources
Full Text Sources